Fig. 5

Salicylate treatment of WT and NPC1-KO mice did not mitigate HPβCD-induced threshold shifts. a-b Schematic representation of the protocol for oral administration (a) and intraperitoneal injection (b) of salicylate. c-d ABR (c) and DPOAE (d) thresholds of WT and NPC1-KO mice at 12 kHz before and after high-dose (8000 mg/kg) HPβCD injection. Base, baseline controls; HP, regular water, 8000 mg/kg HPβCD injection; Sal (O), 3 mg/ml salicylate water for 7 days before HPβCD injection; HP + Sal (O), 3 mg/ml salicylate water for 7 days before and 1 day after HPβCD injection; Sal (IP) 245 mg/kg salicylate injections; HP + Sal (IP), 245 mg/kg salicylate injections before HPβCD injection. For WT, Base: n = 12 (P22–53); HP: n = 2 for ABR (1 male 1 female), n = 4 for DPOAE (2 males, 2 females, P47–57); Sal (O): n = 4 (2 males, 2 females; P50); HP + Sal (O): n = 4 (2 males, 2 females; P52). For NPC1-KO, Base: n = 16 (P21–54); HP: n = 4 (2 males, 2 females; P47–57); Sal (O): n = 5 (2 males 3 females; P = 39–41); Sal (IP): n = 5 (3 males 2 females; P = 31–47); HP + Sal (O): n = 5 (2 males 3 females; P41–48); HP + Sal (IP): n = 4 (2 males 2 females; P33–49). One-way ANOVA with Tukey’s post analysis showed no significant (n.s.) difference between Base vs. Sal (O) or HP vs. HP + Sal (O) or HP + Sal (IP) groups in both WT and NPC1-KO; Sal (IP) groups in WT and NPC1-KO showed statistically significant threshold shifts as compared to Base (P values as indicated)